Characteristics at the time of initiation of first-line therapy and their association with survival in 587 patients with symptomatic Waldenström macroglobulinemia
| Characteristic . | No. (%) of patients . | Median survival . | 95% CI . | P . |
|---|---|---|---|---|
| Sex | ||||
| Male | 373 (64) | 85 | 65-98 | |
| Female | 212 (36) | 89 | 79-110 | .74 |
| Age | ||||
| 65 y or less | 254 (43) | 141 | 120-53 | |
| More than 65 y | 333 (57) | 56 | 49-63 | < .001 |
| Criteria for treatment initiation | ||||
| Cytopenia* | ||||
| Absent | 285 (49) | 92 | 84-20 | |
| Present | 300 (51) | 77 | 60-90 | .03 |
| Organomegaly* | ||||
| Absent | 380 (65) | 89 | 79-106 | |
| Present | 207 (35) | 80 | 64-143 | .84 |
| IgM-related symptoms* | ||||
| Absent | 506 (87) | 84 | 74-98 | |
| Present | 77 (13) | 94 | 87-174 | .27 |
| Hyperviscosity* | ||||
| Absent | 401 (69) | 85 | 79-103 | |
| Present | 183 (31) | 80 | 57-117 | .35 |
| Constitutional symptoms* | ||||
| Absent | 323 (56) | 89 | 79-110 | |
| Present | 255 (44) | 85 | 60-119 | .18 |
| Time from diagnosis to treatment initiation | ||||
| Less than 4 mo | 406 (83) | 89 | 79-118 | |
| 4 mo or more | 181 (17) | 85 | 54-106 | .14 |
| Hemoglobin, g/dL* | ||||
| 11.5 or less | 381 (65) | 123 | 110-179 | |
| More than 11.5 | 205 (35) | 72 | 62-84 | < .001 |
| Platelet count, ×109/L* | ||||
| 100 or less | 54 (9) | 51 | 32-59 | |
| More than 100 | 531 (91) | 90 | 83-116 | < .001 |
| Absolute neutrophil count, ×109/L* | ||||
| 1.5 or less | 53 (9) | 46 | 27-74 | |
| More than 1.5 | 512 (91) | 89 | 80-103 | .002 |
| Serum monoclonal protein, g/dL* | ||||
| 7.0 or less | 541 (93) | 90 | 82-110 | |
| More than 7.0 | 43 (7) | 49 | 37-62 | .002 |
| Serum albumin, g/dL* | ||||
| 3.5 or less | 197 (36) | 79 | 55-89 | |
| More than 3.5 | 354 (64) | 106 | 92-137 | .001 |
| Serum β2-microglobulin, mg/L | ||||
| 3 or less | 251 (44) | 122 | 103-141 | |
| More than 3 | 326 (56) | 63 | 55-83 | < .001 |
| Treatment | ||||
| Alkylating agents | 369 (63) | 85 | 74-103 | |
| Fludarabine (alone or in combination) | 195 (33) | 85 | 61-NR | |
| Rituximab | 23 (4) | NR | 30-NR | .30 |
| Characteristic . | No. (%) of patients . | Median survival . | 95% CI . | P . |
|---|---|---|---|---|
| Sex | ||||
| Male | 373 (64) | 85 | 65-98 | |
| Female | 212 (36) | 89 | 79-110 | .74 |
| Age | ||||
| 65 y or less | 254 (43) | 141 | 120-53 | |
| More than 65 y | 333 (57) | 56 | 49-63 | < .001 |
| Criteria for treatment initiation | ||||
| Cytopenia* | ||||
| Absent | 285 (49) | 92 | 84-20 | |
| Present | 300 (51) | 77 | 60-90 | .03 |
| Organomegaly* | ||||
| Absent | 380 (65) | 89 | 79-106 | |
| Present | 207 (35) | 80 | 64-143 | .84 |
| IgM-related symptoms* | ||||
| Absent | 506 (87) | 84 | 74-98 | |
| Present | 77 (13) | 94 | 87-174 | .27 |
| Hyperviscosity* | ||||
| Absent | 401 (69) | 85 | 79-103 | |
| Present | 183 (31) | 80 | 57-117 | .35 |
| Constitutional symptoms* | ||||
| Absent | 323 (56) | 89 | 79-110 | |
| Present | 255 (44) | 85 | 60-119 | .18 |
| Time from diagnosis to treatment initiation | ||||
| Less than 4 mo | 406 (83) | 89 | 79-118 | |
| 4 mo or more | 181 (17) | 85 | 54-106 | .14 |
| Hemoglobin, g/dL* | ||||
| 11.5 or less | 381 (65) | 123 | 110-179 | |
| More than 11.5 | 205 (35) | 72 | 62-84 | < .001 |
| Platelet count, ×109/L* | ||||
| 100 or less | 54 (9) | 51 | 32-59 | |
| More than 100 | 531 (91) | 90 | 83-116 | < .001 |
| Absolute neutrophil count, ×109/L* | ||||
| 1.5 or less | 53 (9) | 46 | 27-74 | |
| More than 1.5 | 512 (91) | 89 | 80-103 | .002 |
| Serum monoclonal protein, g/dL* | ||||
| 7.0 or less | 541 (93) | 90 | 82-110 | |
| More than 7.0 | 43 (7) | 49 | 37-62 | .002 |
| Serum albumin, g/dL* | ||||
| 3.5 or less | 197 (36) | 79 | 55-89 | |
| More than 3.5 | 354 (64) | 106 | 92-137 | .001 |
| Serum β2-microglobulin, mg/L | ||||
| 3 or less | 251 (44) | 122 | 103-141 | |
| More than 3 | 326 (56) | 63 | 55-83 | < .001 |
| Treatment | ||||
| Alkylating agents | 369 (63) | 85 | 74-103 | |
| Fludarabine (alone or in combination) | 195 (33) | 85 | 61-NR | |
| Rituximab | 23 (4) | NR | 30-NR | .30 |
CI indicates confidence interval; and NR, not reached.
Data were unavailable for some patients.